Mostrar el registro sencillo del ítem

dc.contributor.author
Pérez Lloret, Santiago  
dc.contributor.author
Rascol, Olivier  
dc.date.available
2018-04-11T21:10:56Z  
dc.date.issued
2016-02  
dc.identifier.citation
Pérez Lloret, Santiago; Rascol, Olivier; The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease; Taylor & Francis; Expert Review of Neurotherapeutics; 16; 3; 2-2016; 245-258  
dc.identifier.issn
1744-8360  
dc.identifier.uri
http://hdl.handle.net/11336/41809  
dc.description.abstract
Safinamide (brand name Xadago®, Zambon S.p.A) is a third-generation reversible MAO-B inhibitor, which also blocks sodium voltage-sensitive channels and modulates stimulated release of glutamate. Safinamide was recently licensed by EMA for the treatment of PD as add-on therapy to a stable dose of levodopa alone or in combination with other PD medicinal products in mid-to advanced-stage fluctuating patients. It is also under review by the US FDA. Studies in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys and 6OHDA-lesioned rats suggest antiparkinsonian efficacy and antidyskinesic effects. Randomized, double-blind, placebo-controlled trials have shown efficacy for the treatment of motor symptoms in stable PD patients on dopamine agonists and in fluctuating PD patients on levodopa. Significant improvement in daily ON time was also observed in the latter. This effect was maintained for at least 2 years in double-blind conditions and, interestingly, without significant worsening of dyskinesia. Clinical studies have not detected any specific safety issue other than those already known with MAO-B inhibitors.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Enfermedad de Parkinson  
dc.subject
Safinamida  
dc.subject
Tratamiento  
dc.subject
Inhibidores Mao-B  
dc.subject.classification
Medicina Critica y de Emergencia  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-04-10T20:29:09Z  
dc.journal.volume
16  
dc.journal.number
3  
dc.journal.pagination
245-258  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina  
dc.description.fil
Fil: Rascol, Olivier. Universite Toulose 3; Francia. Inserm; Francia  
dc.journal.title
Expert Review of Neurotherapeutics  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/14737175.2016.1150783?journalCode=iern20  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1586/14737175.2016.1150783